Overview
Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2023-03-01
2023-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to compare pharmacokinetics and safety of Irbesartan and Amlodipine Fixed Dose Combination and coadministration of mono compounds in healthy adult volunteersPhase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Handok Inc.Treatments:
Amlodipine
Irbesartan
Criteria
Inclusion Criteria:- Patients who are 19 years or older on screening
- Signed informed consent
- Healthy Volunteer
- Other inclusion applies
Exclusion Criteria:
- Clinically relevant/significant findings as evaluated by the investigator
- Other exclusion applied